2024
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 657-671. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitro
2015
GLP‐2 reprograms glucose metabolism in intestinal stem cells
Shi X, Alves T, Zeng X, Kibbey R, Estes M, Guan X. GLP‐2 reprograms glucose metabolism in intestinal stem cells. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.851.4.Peer-Reviewed Original ResearchMetabolic reprogrammingIntestinal stem cellsCell proliferationMetabolic fluxStem cellsAmino acid biosynthesisGlycolysis-dependent mannerDe novo biosynthesisPyruvate kinase M2Reprograms glucose metabolismIntracellular metabolic fluxesCellular functionsAcid biosynthesisCrypt stem cellsNovo biosynthesisReprogrammingNovel roleKinase M2Aerobic glycolysisBiosynthesisGLP-2Intestinal crypt cell proliferationNuclear translocationCellular mechanismsGlycolytic intermediates